Home / Expertise / Life Sciences & Healthcare
side view of scientist looking into microscope in bright research lab

Life Sciences & Healthcare

Peru

CMS is an international leader in the Life Sciences & Healthcare Sector, with over 150 specialized lawyers and 100 Lifesciences companies as clients, including the top 20 global pharmaceutical companies and nine out of top ten global medical device companies.

In CMS Grau, our lawyers have extensive experience, having advised local and international investors in the areas of pharmaceuticals, agriculture, biotechnology and medical services.

Our multidisciplinary team of lawyers joins efforts to provide our clients with advice in a wide range of legal aspects that cover their businesses, such as regulatory, product liability, competition, public procurement, intellectual property, corporate and commercial issues; as well as disputes and mergers and acquisitions.

In Peru our lawyers have been involved in the working groups that developed the Regulations to the Sanitary Registry administered by the General Bureau of Medicines, Consumables and Drugs; and the Law for Pharmaceutical Centers. 

Read more Read less

Feed

Show only
CMS Ex­pert Guide to Ad­vert­ising of Medi­cines and Med­ic­al...
22 May 20
For­eign in­vest­ments in Ger­man life sci­ence com­pan­ies be­come sub­ject...
In re­sponse to the COV­ID-19 pan­dem­ic, Ger­many has widened the scope of its in­vest­ment con­trol to in­clude nu­mer­ous life sci­ence com­pan­ies. The amend­ments to the For­eign Trade and Pay­ments Or­din­ance ("AWV")...
CMS Ex­pert Guide to a Leg­al Roadmap to Can­nabis
04 May 20
EPO Board of ap­peal re­mits to ex­amin­ing di­vi­sion when pri­or art search...
In Mod­el de­term­in­a­tion sys­tem/Ac­cen­ture Glob­al Ser­vices Lim­ited (Case T-1159/15), the board of ap­peal finds that need to per­form a pri­or art search con­sti­tutes a spe­cial reas­on to re­mit the ap­peal ap­plic­a­tion...
Dec 2018
CMS Life Sci­ences & Health­care Sec­tor Group: An over­view...
30 Apr 20
USPTO finds an in­ven­tion cre­ated by an AI ma­chine is not pat­entable
The US Pat­ent and Trade Mark Of­fice has found that DABUS is not a per­son and so can­not be con­sidered an in­vent­or of a pat­ent. DABUS is an ar­ti­fi­cial in­tel­li­gence (AI) ma­chine. The USPTO ac­cep­ted the in­dic­a­tion...
17 Mar 20
While doc­tors fight COV­ID-19 au­thor­it­ies battle fraud, price hikes...
In every coun­try hit by COV­ID-19, the dis­ease linked to the Coronavir­us, com­pet­i­tion and con­sumer pro­tec­tion au­thor­it­ies have been con­fron­ted with the vir­us's im­plic­a­tions. Gov­ern­ments, au­thor­it­ies and...
31 Jan 20
UK In­tel­lec­tu­al Prop­erty Of­fice finds that pat­ent law does not cater...
The UK In­tel­lec­tu­al Prop­erty Of­fice has found that DABUS is not a per­son and so can­not be con­sidered an in­vent­or of a pat­ent. DABUS is an ar­ti­fi­cial in­tel­li­gence (AI) ma­chine. The UKIPO ac­cep­ted the in­dic­a­tion...
24 Aug 18
Gov­ern­ment Is­sues Brexit Tech­nic­al No­tice for Life Sci­ences
On 23 Au­gust 2018, the UK Gov­ern­ment (the "Gov­ern­ment") is­sued the first wave of its tech­nic­al pa­pers de­signed to provide guid­ance to com­pan­ies to help pre­pare for a "No Deal" Brexit. In this scen­ario,...